You are viewing the site in preview mode
Skip to main content
| |
HIV
|
HIV/HCV
|
p-value
|
|---|
|
No
|
27
|
28
| |
|
Age (years)
|
51 (46; 53)
|
48.5 (45.5; 53)
|
0.272
|
|
Gender (male)
|
16 (59.3%)
|
19 (67.9%)
|
0.508
|
|
BMI (kg/m2)
|
25 (23.4; 26.7)
|
24 (20.8; 26)
|
0.125
|
|
BMI ≥ 25 (kg/m2)
|
14 (51.9%)
|
9 (32.1%)
|
0.139
|
|
Diabetes
|
4 (14.8%)
|
2 (7.1%)
|
0.362
|
|
High alcohol intake
|
1 (3.7%)
|
13 (46.4%)
|
< 0.001
|
|
HIV acquired by IVDU
|
0 (0%)
|
22 (78.6%)
|
< 0.001
|
|
Prior AIDS
|
10 (37%)
|
8 (28.6%)
|
0.504
|
|
Years since HIV infection
| |
22.5 (17.5; 26.5)
|
–
|
|
Years since HCV diagnosis
| |
13 (12; 23)
|
–
|
|
Previous HCV therapy (IFNα + rib)
| |
13 (46.4%)
|
–
|
|
Antiretroviral therapy
|
27 (100%)
|
28 (100%)
|
0.999
|
|
PI-based
|
6 (22.2%)
|
6(21.43%)
|
0.019
|
|
2NRTI + II-based
|
3 (11.1%)
|
11 (39.3%)
| |
|
2NRTI + PI-based
|
0 (0%)
|
3 (10.7%)
| |
|
2NRTI + NNRTI-based
|
16 (59.3%)
|
7 (25%)
| |
|
Others
|
2 (7.4%)
|
1 (3.6%)
| |
|
HIV markers
|
|
Nadir CD4 + T-cells
|
261 (99; 402)
|
185 (72; 269)
|
0.155
|
|
Nadir CD4 + T-cells < 200 cells/mm3
|
11 (44%)
|
15 (53.6%)
|
0.487
|
|
CD4 + T-cells
|
804 (685; 1036)
|
678.5 (446.5; 906)
|
0.026
|
|
CD4 + T-cells < 500 cells/mm3
|
0 (0%)
|
8 (28.6%)
|
0.003
|
|
HIV-RNA > 50 cp/mL
|
0 (0%)
|
0 (0%)
|
–
|
|
HCV markers
|
|
HCV genotype
|
|
1
| |
18 (64.3%)
|
–
|
|
2
| |
1 (3.6%)
| |
|
3
| |
8 (28.6%)
| |
|
4
| |
1 (3.6%)
| |
|
Log10 HCV-RNA (IU/mL)
| |
6.3 (5.8; 6.6)
|
–
|
|
HCV-RNA > 850.000 IU/mL
| |
19 (67.9%)
|
–
|
|
Non-invasive fibrosis indexes
|
|
FIB-4
|
1 (0.9; 1.2)
|
2.6 (1.9; 3.2)
|
< 0.001
|
|
FIB-4 ≥ 3.25
|
0 (0%)
|
7 (25%)
|
0.006
|
|
LSM (Kpa)
| |
11.9 (9.7; 19.2)
|
–
|
|
F0–F1 (< 7.1 kPa)
| |
2 (7.1%)
|
–
|
|
F2 (7.1–9.4 kPa)
| |
5 (17.9%)
| |
|
F3 (9.5–12.4 kPa)
| |
8 (28.6%)
| |
|
F4 (≥ 12.5 kPa)
| |
13 (46.4%)
| |
- Statistics: The values are expressed as the absolute number (percentage) and median (interquartile range). P-values were calculated by Mann–Whitney and chi-squared tests
- HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; LSM, liver stiffness measure; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug user; AIDS, acquired immune deficiency syndrome; IFNα + rib, interferon-alpha plus ribavirin; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; NRTI, nucleoside analogue HIV reverse; BMI, body mass index
